Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209417 | 0.98 | GAA (0.46) | GAAFKBP1ACA1CA2POLB | |
| SCHEMBL15018117 | 0.93 | GAA (0.42) | GAAFKBP1ACA1CA2POLB | |
| SCHEMBL13249203 | 0.80 | GAA (0.47) | GAAFKBP1ACA1CA2POLB | |
| SCHEMBL19631003 | 0.80 | GAA (0.47) | GAAFKBP1ACA1CA2POLB | |
| SCHEMBL4664950 | 0.80 | CA1 (0.46) | GAAFKBP1ACA1CA2POLB | |
| SCHEMBL1705467 | 0.79 | GAA (0.46) | GAAFKBP1ACA1CA2POLB | |
| SCHEMBL25229177 | 0.78 | KDM4E (0.42) | GAACA1CA2POLBKMT2A | |
| SCHEMBL3208631 | 0.78 | CA12 (0.48) | POLBTSHRL3MBTL1 | |
| SCHEMBL3207323 | 0.78 | SMN1; SMN2 (0.40) | GAAHPGDL3MBTL1 | |
| SCHEMBL28843872 | 0.78 | POLB (0.60) | GAAFKBP1APOLBKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1404829-A | Double inhibitor synthesized by wax ester and cholesterol ester for inbibiting generation of sebum | WARNER LAMBERT CO (US) | 2003-03-26 | — | — | CN | claimed |
| CN-1370526-A | Treating method of nuclear factor-KB mediated diseases and dysfuction | WANER LONGBER CO (US) | 2002-09-25 | — | — | CN | claimed |
| EP-4121031-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | Atux Iskay LLC (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20220227707-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-21 | — | — | US | disclosed |
| EP-3914583-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020154321-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| CN-1404829-A | Double inhibitor synthesized by wax ester and cholesterol ester for inbibiting generation of sebum | WARNER LAMBERT CO (US) | 2003-03-26 | — | — | CN | disclosed |
| CN-1370526-A | Treating method of nuclear factor-KB mediated diseases and dysfuction | WANER LONGBER CO (US) | 2002-09-25 | — | — | CN | disclosed |
| EP-0592439-A1 | AMINOSULFONYL CARBAMATES | WARNER-LAMBERT COMPANY (US) | 1994-04-20 | — | — | EP | disclosed |
| WO-1992008693-A1 | AMINOSULFONYL CARBAMATES | WARNER-LAMBERT COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | GAA 76/4885FKBP1A 1970/4885CA1 1123/4885 |
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | GAA 208/4885FKBP1A 1340/4885CA1 3460/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | GAA 329/4885FKBP1A 1341/4885CA1 3746/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | GAA 208/4885FKBP1A 1340/4885CA1 3460/4885 |
| US-20220227707-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | GAA 1446/4885FKBP1A 1311/4885CA1 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.